Evidence map›Paper›PMID 38226698›Full record

ArticleBrain : a journal of neurology2024

TREM2 variants that cause early dementia and increase Alzheimer's disease risk affect gene splicing.

Kostantin Kiianitsa, Maria E Lukes, Brian J Hayes, Julianna N Brutman, Paul N Valdmanis, Thomas D Bird, Wendy H Raskind, Olena Korvatska

Open access · greenAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Genetic and environmental risk factors for dementia in African adults: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Trem2bioRxiv : the preprint server for biology · 2025
    Article
  8. Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kostantin KiianitsaDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-9572-3591
Maria E LukesDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Brian J HayesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Julianna N BrutmanDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Paul N ValdmanisDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-8840-6969
Thomas D BirdDepartment of Neurology, University of Washington, Seattle, WA 98195, USA.
Wendy H RaskindDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Olena KorvatskaDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-0070-000X
University of Washington Medical Center · USUniversity of Puget Sound · USUniversity of Washington · USFred Hutch Cancer Center · US

Funding

University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0M
Novel approaches to identify tandem repeat expansions in neurodegenerative diseaseR01NS122766 · NINDS · UNIVERSITY OF WASHINGTON · PI Paul Nils Valdmanis · 2022 to 2026
$1.9M
Genetic Movement Disorders: Etiologies and PathogenesesI01CX001702 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI CYRUS P ZABETIAN · 2018 to 2026
–
CSRD VA I01 CX001702NIA NIH HHS P30 AG066509NIA NIH HHS R01NS122766NINDS NIH HHS R01 NS122766Royalty Research Fund of the University of Washington A167463The Takayama family giftUS Department of Veterans Affairs Clinical Sciences R&D Service Merit Review 101 CX001702
6 · The paper itself

Abstract

Loss-of-function variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are responsible for a spectrum of neurodegenerative disorders. In the homozygous state, they cause severe pathologies with early onset dementia, such as Nasu-Hakola disease and behavioural variants of frontotemporal dementia (FTD), whereas heterozygous variants increase the risk of late-onset Alzheimer's disease (AD) and FTD. For over half of TREM2 variants found in families with recessive early onset dementia, the defect occurs at the transcript level via premature termination codons or aberrant splicing. The remaining variants are missense alterations thought to affect the protein; however, the underlying pathogenic mechanism is less clear. In this work, we tested whether these disease-associated TREM2 variants contribute to the pathology via altered splicing. Variants scored by SpliceAI algorithm were tested by a full-size TREM2 splicing reporter assay in different cell lines. The effect of variants was quantified by qRT-/RT-PCR and western blots. Nanostring nCounter was used to measure TREM2 RNA in the brains of NHD patients who carried spliceogenic variants. Exon skipping events were analysed from brain RNA-Seq datasets available through the Accelerating Medicines Partnership for Alzheimer's Disease Consortium. We found that for some Nasu-Hakola disease and early onset FTD-causing variants, splicing defects were the primary cause (D134G) or likely contributor to pathogenicity (V126G and K186N). Similar but milder effects on splicing of exons 2 and 3 were demonstrated for A130V, L133L and R136W enriched in patients with dementia. Moreover, the two most frequent missense variants associated with AD/FTD risk in European and African ancestries (R62H, 1% in Caucasians and T96K, 12% in Africans) had splicing defects via excessive skipping of exon 2 and overproduction of a potentially antagonistic TREM2 protein isoform. The effect of R62H on exon 2 skipping was confirmed in three independent brain RNA-Seq datasets. Our findings revealed an unanticipated complexity of pathogenic variation in TREM2, in which effects on post-transcriptional gene regulation and protein function often coexist. This necessitates the inclusion of computational and experimental analyses of splicing and mRNA processing for a better understanding of genetic variation in disease.

Indexed as

Alzheimer DiseaseMembrane GlycoproteinsReceptors, ImmunologicRNA SplicingDementiaFrontotemporal DementiaGenetic Predisposition to DiseaseHumansMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanalternative splicingbrainexon skippinggene dosagemicroglianeurodegeneration

Identifiers

PMID38226698
PMCPMC11224616
OpenAlexW4390919914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.